Chronicl-DOPA treatment differentially regulates gene expression of glutamate decarboxylase, preproenkephalin and preprotachykinin in the striatum of 6-hydroxydopamine-lesioned rat
暂无分享,去创建一个
P. Jenner | C. Marsden | P. Jenner | B. Zeng | J. Jolkkonen | C. D. Marsden | B. -Y. Zeng | J. Jolkkonen
[1] J. Cadet,et al. Quantitative in situ hybridization evidence for differential regulation of proenkephalin and dopamine D2 receptor mRNA levels in the rat striatum: effects of unilateral intrastriatal injections of 6-hydroxydopamine. , 1992, Brain research. Molecular brain research.
[2] Y. Agid,et al. Continuous and intermittent levodopa differentially affect basal ganglia function , 1989, Annals of neurology.
[3] A. Crossman,et al. A hypothesis on the pathophysiological mechanisms that underlie levodopa‐ or dopamine agonist‐induced dyskinesia in Parkinson's disease: Implications for future strategies in treatment , 1990, Movement disorders : official journal of the Movement Disorder Society.
[4] Allan J. Tobin,et al. Parallel increases in striatal glutamic acid decarboxylase activity and mRNA levels in rats with lesions of the nigrostriatal pathway , 1990, Brain Research.
[5] J. Penney,et al. The functional anatomy of basal ganglia disorders , 1989, Trends in Neurosciences.
[6] T. Bonner,et al. Mesencephalic dopamine neurons regulate the expression of neuropeptide mRNAs in the rat forebrain. , 1986, Proceedings of the National Academy of Sciences of the United States of America.
[7] H. Groenewegen,et al. Increase of enkephalin and decrease of substance P immunoreactivity in the dorsal and ventral striatum of the rat after midbrain 6-hydroxydopamine lesions , 1987, Brain Research.
[8] C. Gerfen,et al. D1 and D2 dopamine receptor-regulated gene expression of striatonigral and striatopallidal neurons. , 1990, Science.
[9] G. Paxinos,et al. The Rat Brain in Stereotaxic Coordinates , 1983 .
[10] F. Gage,et al. Intracerebral grafting of neuronal cell suspensions. III. Activity of intrastriatal nigral suspension implants as assessed by measurements of dopamine synthesis and metabolism. , 1983, Acta physiologica Scandinavica. Supplementum.
[11] R. Robertson,et al. Chronic continuous and intermittentl-3,4-dihydroxyphenylalanine treatments differentially affect basal ganglia function in 6-hydroxydopamine lesioned rats—an autoradiographic study using [3H]flunitrazepam , 1993, Neuroscience.
[12] A. Tobin,et al. Glutamic acid decarboxylase cDNA: nucleotide sequence encoding an enzymatically active fusion protein , 1987, The Journal of neuroscience : the official journal of the Society for Neuroscience.
[13] N. Lindefors,et al. Midbrain dopamine neurons regulate preprotachykinin-A mRNA expression in the rat forebrain during development. , 1992, Brain research. Molecular brain research.
[14] C. Marsden,et al. L-DOPA reverses altered gene expression of substance P but not enkephalin in the caudate-putamen of common marmosets treated with MPTP. , 1995, Brain research. Molecular brain research.
[15] B. Sahakian,et al. Circling behavior in rats with partial, unilateral nigro-striatal lesions: Effect of amphetamine, apomorphine, and DOPA , 1980, Pharmacology Biochemistry and Behavior.
[16] L. Pellegrino,et al. stereotaxic atlas of the rat brain , 1967 .
[17] Z. Susel,et al. Chronic levodopa treatment alters basal and dopamine agonist-stimulated cerebral glucose utilization , 1990, The Journal of neuroscience : the official journal of the Society for Neuroscience.
[18] J. Chirgwin,et al. Three rat preprotachykinin mRNAs encode the neuropeptides substance P and neurokinin A. , 1987, Proceedings of the National Academy of Sciences of the United States of America.
[19] C. Feuerstein,et al. Similar Time Course Changes in Striatal Levels of Glutamic Acid Decarboxylase and Proenkephalin mRNA Following Dopaminergic Deafferentation in the Rat , 1988, Journal of neurochemistry.
[20] T. Engber,et al. Continuous and intermittent levodopa differentially affect rotation induced by D-1 and D-2 dopamine agonists. , 1989, European journal of pharmacology.
[21] A. Prince,et al. HEPANOSTICON IN SCREENING FOR HBsAg , 1975, The Lancet.
[22] J. Bartko,et al. Motor fluctuations in Parkinson's disease: Central pathophysiological mechanisms, part II , 1988, Annals of neurology.
[23] A. Crossman,et al. Primate models of dyskinesia: The experimental approach to the study of basal ganglia-related involuntary movement disorders , 1987, Neuroscience.
[24] A. Reiner,et al. The patterns of neurotransmitter and neuropeptide co-occurrence among striatal projection neurons: conclusions based on recent findings , 1990, Brain Research Reviews.
[25] C. Marsden,et al. SUCCESS AND PROBLEMS OF LONG-TERM LEVODOPA THERAPY IN PARKINSON'S DISEASE , 1977, The Lancet.
[26] R. Aft,et al. Hemin-mediated oxidative degradation of proteins. , 1984, The Journal of biological chemistry.
[27] S. Afsharpour,et al. The glutamate decarboxylase-, leucine enkephalin-, methionine enkephalin-and substance P-immunoreactive neurons in the neostriatum of the rat and cat: Evidence for partial population overlap , 1986, Neuroscience.
[28] M. Garcia-Munoz,et al. Changes in the activity of GAD in the basal ganglia of the rat after striatal dopaminergic denervation , 1987, Neuropharmacology.
[29] C. Gerfen,et al. Levodopa replacement therapy alters enzyme activities in striatum and neuropeptide content in striatal output regions of 6-hydroxydopamine lesioned rats , 1991, Brain Research.
[30] M. Chesselet,et al. Messenger RNAs encoding glutamate-decar☐ylases are differentially affected by nigrostriatal lesions in subpopulations of striatal neurons , 1992, Brain Research.
[31] C. Marsden,et al. Preproenkephalin and preprotachykinin messenger RNA expression in normal human basal ganglia and in Parkinson's disease , 1995, Neuroscience.
[32] T. Chase,et al. Motor fluctuations in Parkinson's disease: Pathogenetic and therapeutic studies , 1987, Annals of neurology.
[33] C. Marsden,et al. Effects of a unilateral 6-hydroxydopamine lesion and prolonged L-3,4-dihydroxyphenylalanine treatment on peptidergic systems in rat basal ganglia. , 1992, European journal of pharmacology.